Showing 501-510 of 9358 results for "".
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate customers, such as Macy's Blue Mercu…
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and Element Eight. The ECHO2 Plus Oxygen Treatment System employs pure oxygen gas, along with vita…
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in Arena Pharmaceuticals, Inc.’s Phase 2 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe alopecia areata. The randomize…
- LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidatehttps://practicaldermatology.com/news/leo-pharma-enters-license-agreement-with-oneness-biotech-microbio-shanghai-for-atopic-dermatitis-and-asthma-drug-candidate/2460353/LEO Pharma A/S has signed a worldwide exclusive licensing agreement with Oneness Biotech of Taiwan and Microbio Shanghai of China, covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825. FB825 is a first-in-class drug candidate …
- New from Lumenis: Meet the Stellar M22 Platformhttps://practicaldermatology.com/news/new-from-lumenis-meet-the-stellar-m22-platform/2460300/Lumenis Ltd. is launching the Stellar M22, a multi-application platform that builds on the heritage of the M22 by adding even more bells and whistles. The new Stellar M22 is now available in the USA and Europe. "Lumenis is thrilled to introduce the new Stellar M22, our next-generation in multi-ap…
- Soliton Takes On Cellulitehttps://practicaldermatology.com/news/soliton-takes-on-cellulite-2/2460049/Soliton, Inc.’s Rapid Acoustic Pulse ("RAP") device may selectively disrupt of the fibrotic septa that contribute to the appearance of cellulite, according to preclinical studies. The device is cleated for use in tattoo removal, however, technology for the treatment of cellulite is investigational…
- Senté to Introduce Intensive Bio Complete Creamhttps://practicaldermatology.com/news/sent-to-introduce-intensive-bio-complete-cream/2459927/Senté is expanding their family of skincare products with the upcoming launch of Intensive Bio Complete Cream. Slated to be available on Feb. 11, 2019, the new nighttime cream is an “advanced retinol,” explains Virginia L. Vega, Ph.D., Senté ’s Vice President, Research & Development and Physician …
- Bonti Takes Aim at Scar Reduction with Shine Clinical Programhttps://practicaldermatology.com/news/bonti-takes-aim-at-scar-reduction-with-shine-clinical-program/2457897/Bonti has begun their SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. EB- 001 is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique product profile, characterized by fast onset of action (within 24 hours) and a sh…
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factors associated with metastasis, originally discover…
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The BLA filing for tildrakizumab was submitted by Merck &…